natgillin/translations-raw huggingface dataset:
TAXOTERE 160 mg/8 ml concentrate for solution for infusion requires NO prior dilution with a solvent and is ready to add to the infusion solution.
TAXOTERE 160 mg/8 ml koncentrat za otopinu za infuziju NE zahtijeva prethodno razrjeđivanje otapalom te se može odmah dodati u infuzijsku vrećicu.
TAXOTERE 160 mg/8 ml concentrate for solution for infusion.
TAXOTERE 160 mg/8 ml koncentrat za otopinu za infuziju
TAXOTERE 160 mg/8 ml sterile concentrate docetaxel
TAXOTERE 160 mg/8 ml sterilni koncentrat docetaksel
TAXOTERE 20 mg/0.5 ml concentrate and solvent for solution for infusion
TAXOTERE 20 mg/0,5 ml koncentrat i otapalo za otopinu za infuziju
TAXOTERE 20 mg/0.5 ml concentrate and solvent for solution for infusion docetaxel
TAXOTERE 20 mg/0,5 ml koncentrat i otapalo za otopinu za infuziju docetaksel
TAXOTERE 20 mg/0.5 ml concentrate for solution for infusion docetaxel intravenous use
TAXOTERE 20 mg/0,5 ml koncentrat za otopinu za infuziju docetaksel za primjenu u venu
TAXOTERE 20 mg/0.5 ml concentrate for solution for infusion is a clear viscous, yellow to brown- yellow solution containing 40 mg/ml docetaxel (anhydrous) in polysorbate 80 and citric acid.
TAXOTERE 20 mg/0,5 ml koncentrat za otopinu za infuziju bistra je viskozna, žuta do žutosmeđa otopina koja sadrži 40 mg/ml docetaksela (bezvodnog) u polisorbatu 80 i citratnoj kiselini.
TAXOTERE 20 mg/0.5 ml concentrate for solution for infusion is a clear viscous, yellow to brown- yellow solution.
TAXOTERE 20 mg/0,5 ml koncentrat za otopinu za infuziju je prozirna, viskozna, žuta do smeđežuta otopina.
TAXOTERE 20 mg/0.5 ml vial
TAXOTERE 20 mg/0,5 ml bočica
TAXOTERE 20 mg/1 ml concentrate for solution for infusion
TAXOTERE 20 mg/1 ml koncentrat za otopinu za infuziju
TAXOTERE 20 mg/1 ml concentrate for solution for infusion requires NO prior dilution with a solvent and is ready to add to the infusion solution.
TAXOTERE 20 mg/1 ml koncentrat za otopinu za infuziju NE zahtijeva prethodno razrjeđivanje otapalom te se može odmah dodati u infuzijsku vrećicu.
TAXOTERE 20 mg/1 ml sterile concentrate docetaxel
TAXOTERE 20 mg/1 ml sterilni koncentrat docetaksel
TAXOTERE 80 mg/2 ml concentrate and solvent for solution for infusion
TAXOTERE 80 mg/2 ml koncentrat i otapalo za otopinu za infuziju
TAXOTERE 80 mg/2 ml concentrate for solution for infusion docetaxel intravenous use
TAXOTERE 80 mg/2 ml koncentrat za otopinu za infuziju docetaksel za primjenu u venu
TAXOTERE 80 mg/2 ml concentrate for solution for infusion is a clear viscous, yellow to brown- yellow solution containing 40 mg/ml docetaxel (anhydrous) in polysorbate 80 and citric acid.
TAXOTERE 80 mg/2 ml koncentrat za otopinu za infuziju bistra je viskozna, žuta do žutosmeđa otopina koja sadrži 40 mg/ml docetaksela (bezvodnog) u polisorbatu 80 i citratnoj kiselini.
TAXOTERE 80 mg/2 ml concentrate for solution for infusion is a clear viscous, yellow to brown- yellow solution.
TAXOTERE 80 mg/2 ml koncentrat za otopinu za infuziju je prozirna, viskozna, žuta do smeđežuta otopina.
TAXOTERE 80 mg/2 ml vial
TAXOTERE 80 mg/2 ml bočica
TAXOTERE 80 mg/4 ml concentrate for solution for infusion
TAXOTERE 80 mg/4 ml koncentrat za otopinu za infuziju
TAXOTERE 80 mg/4 ml concentrate for solution for infusion requires NO prior dilution with a solvent and is ready to add to the infusion solution.
TAXOTERE 80 mg/4 ml koncentrat za otopinu za infuziju NE zahtijeva prethodno razrjeđivanje otapalom te se može odmah dodati u infuzijsku vrećicu.
TAXOTERE 80 mg/4 ml sterile concentrate docetaxel
TAXOTERE 80 mg/4 ml sterilni koncentrat docetaksel
TAXOTERE as single agent
TAXOTERE u monoterapiji
TAXOTERE concentrate for solution for infusion is a pale yellow to brownish-yellow solution.
TAXOTERE koncentrat za otopinu za infuziju je blijedo žuta do smeđežuta otopina.
TAXOTERE has been prescribed by your doctor for the treatment of breast cancer, special forms of lung cancer (non-small cell lung cancer), prostate cancer, gastric cancer or head and neck cancer:
TAXOTERE Vam je propisao liječnik za liječenje karcinoma dojke, posebnih oblika karcinoma pluća (karcinom nemalih stanica pluća), karcinoma prostate, karcinoma želuca ili karcinoma glave i vrata:
TAXOTERE in combination with doxorubicin and cyclophosphamide: adjuvant therapy
TAXOTERE u kombinaciji s doksorubicinom i ciklofosfamidom: adjuvantno liječenje
TAXOTERE in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.
TAXOTERE u kombinaciji s prednizonom ili prednizolonom indiciran je za liječenje bolesnika s metastatskim karcinomom prostate refraktornim na hormonsko liječenje.
TAXOTERE is an antineoplastic agent and, as with other potentially toxic compounds, caution should be exercised when handling it and preparing TAXOTERE solutions.
TAXOTERE je antineoplastična tvar te se njime, kao što je slučaj i sa svim ostalim potencijalno toksičnim spojevima, mora oprezno rukovati u pripremi TAXOTERE otopina.
TAXOTERE was administered as a 1-hour infusion, all other medicinal products were given as intraveinously on day 1 every three weeks.
TAXOTERE se primjenjivao u obliku jednosatne infuzije, a svi ostali lijekovi davali su se intravenski na dan 1 svaka tri tjedna.
taying in cool places;
boravak u hladnim prostorima;
TC (combined group)
TC (kombinirana skupina)
TC (mg/dl)
TG (mg/dl)
TC (mmol/L)
UK (mmol/l)
TC/ HDL- C
TC/ HDL-C
TDF Groupa
Skupina koja je primalaTDFa
TE = Treatment-Experienced (failed prior treatment with interferon [IFN] or peginterferon alfa [peg-IFN] with or without ribavirin (RBV) or were intolerant to prior therapy)
PL = prethodno liječeni (nisu uspješno odgovorili na prethodno liječenje interferonom [IFN] ili peginterferonom alfa [peg-IFN], s ribavirinom [RBV] ili bez njega, ili nisu podnosili prethodnu terapiju)
TE: number of treatment-experienced patients.
TE: broj pacijenata koji su prethodno bili liječeni.
TEa
SVR
Teaching guide to facilitate training of the patients in the safe use of the pre-filled pen
vodič za obuku koji olakšava osposobljavanje bolesnika za sigurnu primjenu napunjene brizgalice
Teaching guide to facilitate training of the patients in the safe use of the pre-filled pen/prefilled syringes
Upute koje olakšavaju obučavanje bolesnika kako primijeniti napunjenu brizgalicu/napunjenu štrcaljku na siguran način.
TEAEs* with Incidence ≥1% in Fampyra vs Placebo
TEAEs* s incidencijom ≥1% u Fampyre u odnosu na placebo
Teal
tirkizna
Tear
Otkinite
Tear
Otrgnite
Tear at notch
Poderite pri zarezanom dijelu
Tear in stomach or intestine wall that can be painful and cause nausea
Probijanje stijenke želuca ili crijeva koje može biti bolno i uzrokovati mučninu
tear in the intestine or inflammation of the stomach lining
puknuće crijeva ili upala želučane sluznice
Tear off the foil wrapper and take out the strip of 5 containers.
Otvorite vrećicu i izvadite jednu pločicu s 5 spremnika.
Tear open along arrows marked on the right side of the sachet as shown in drawing below.
Razderite niz strelice označene na desnoj strani vrećice na način prikazan na donjem crtežu.
Tear open pouch at level of cut.
Vrećicu otvoriti kidanjem na za to predviđenom mjestu.
Tear open sachet (see Figure 3).
Otvorite vrećicu (pogledajte sliku 3).
Tear open the sachet.
Otvorite vrećicu.
Tear or cut sachet open along cut line.
Poderite ili razrežite vrećicu duž oznake za otvaranje.
Tear or hole or bleeding in your stomach or intestine, inflammation or tear of anus, blood clots in lungs, bleeding in lungs or trachea (airway)
Razdor, rupa ili krvarenje u želucu ili crijevima, upala ili razdor anusa, krvni ugrušci u plućima, krvarenje u plućima ili dušniku (dišnim putovima)
Tear-off
Otrgnite
Tear.
Pokidajte.
Tearing of the eye, eye sensitivity to light.
uzenje oka, osjetljivost očiju na svjetlost
Tears
Suzenje
Teaspoon (5 ml spoon)
čajna žličica (žličica od 5 ml)
Tecfidera 120 mg gastro-resistant hard capsules are green and white and printed with ‘BG-12 120 mg’ and are available in packs containing 14 capsules.
Tecfidera 120 mg tvrde želučanootporne kapsule su zelene i bijele boje s otisnutom oznakom ‘BG-12 120 mg’ i dostupne su u pakiranju od 14 kapsula.
Tecfidera 120 mg Gastro-resistant hard capsules Dimethyl fumarate
Tecfidera 120 mg tvrde želučanootporne kapsule dimetilfumarat
Tecfidera 120 mg gastro-resistant hard capsules Tecfidera 240 mg gastro-resistant hard capsules dimethyl fumarate
Tecfidera 120 mg tvrde želučanootporne kapsule Tecfidera 240 mg tvrde želučanootporne kapsule dimetilfumarat (dimethylis fumaras)
Tecfidera 120mg capsule
Tecfidera 120 mg kapsule
Tecfidera 240 mg gastro-resistant hard capsules are green and printed with ‘BG-12 240 mg’ and are available in packs containing 56 or 168 capsules.
Tecfidera 240 mg tvrde želučanootporne kapsule su zelene boje s otisnutom oznakom ‘BG-12 240 mg’ i dostupne su u pakiranju od 56 ili 168 kapsula.
Tecfidera 240 mg Gastro-resistant hard capsules Dimethyl fumarate
Tecfidera 240 mg tvrde želučanootporne kapsule dimetilfumarat
Tecfidera 240 mg twice a day
Tecfidera 240 mg dva puta na dan
Tecfidera 240mg capsule
Tecfidera 240 mg kapsule
Tecfidera has been shown to be effective in reducing the number of relapses in patients with relapsing- remitting MS and in reducing the number of patients who have relapses during treatment.
Dokazano je da je lijek Tecfidera djelotvoran u smanjivanju broja relapsa u bolesnika oboljelih od relapsno-remitirajući MS-a, te da smanjuje broj bolesnika koji ih imaju tijekom liječenja.
Tecfidera has not been studied in patients with pre-existing low lymphocyte counts and caution should be exercised when treating these patients.
Tecfidera nije ispitivana u bolesnika s već postojećim niskim brojem limfocita pa je potreban oprez pri liječenju takvih bolesnika.
Tecfidera has not been studied in patients with renal or hepatic impairment.
Tecfidera nije ispitivana u bolesnika s oštećenjem bubrega ili jetre.
Tecfidera is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (please refer to section 5.1 for important information on the populations for which efficacy has been established).
Tecfidera je indicirana za liječenje odraslih bolesnika s relapsno-remitirajućom multiplom sklerozom (molimo pogledajte dio 5.1 za važne informacije o populacijama za koje je utvrđena djelotvornost).
Tecfidera is not to be used during breast-feeding.
Tecfideru se ne smije uzimati dok dojite.
Tecfidera is used to treat relapsing-remitting multiple sclerosis (MS).
Tecfidera se koristi za liječenje relapsno-remitirajuće multiple skleroze (MS).
Tecfidera may affect your white blood cell counts, your kidneys and liver.
Tecfidera može utjecati na broj Vaših bijelih krvnih stanica, na Vaše bubrege i jetru.
Tecfidera seems to work by stopping the body’s defence system from damaging your brain and spinal cord.
Čini se da Tecfidera djeluje zaustavljajući oštećenja mozga i leđne moždine izazvana djelovanjem obrambenog sustava tijela.
Tecfidera should not be used in children and adolescents below 18 years old.
Djeca i adolescenti ispod 18 godina starosti ne smiju uzimati Tecfideru.
Tecfidera with food and alcohol
Tecfidera s hranom i alkoholom
Technetium (99mTc) is produced by means of a (99Mo/99mTc) generator and decays with the emission of gamma radiation with a mean energy of 140 keV and a half-life of 6.02 hours to technetium (99mTc) which, in view of its long half-life of 2.13 x 105 years can be regarded as quasi stable.
Tehnecij [99mTc] nastaje pomoću (99Mo/99mTc) generatora i raspada se uz emisiju gama zračenja srednje energije 140 keV s poluvijekom od 6,02 sata na tehnecij [99mTc], koji se, s obzirom na svoj dugi poluvijek od 2,13 x 105 godina, može smatrati polustabilnim.
Technetium Tc 99m labelling reactions depend on maintaining the stannous ion in the reduced state.
Reakcije prilikom obilježavanja tehnecijem Tc 99m ovise o održavanju iona kositra u reduciranom stanju.
Technetium Tc 99m tilmanocept binding is independent of tumour type or severity.
Vezivanje tilmanocepta obilježenog radioaktivnim tehnecijem Tc 99m neovisno je o tipu ili stupnju malignosti tumora.
Technetium Tc 99m tilmanocept is eliminated primarily through the kidneys.
Tilmanocept obilježen radiaktivnim tehnecijem Tc 99m eliminira se primarno putem bubrega.
Techniques for intraoperative risk reduction (microsurgical technique, neurophysiological monitoring, choice of approach) and how to implement them;
Tehnike smanjivanja intraoperacijskog rizika (mikrokirurške tehnike, neurofiziološki nadzor, odabir pristupa) i kako ih primijeniti;
Techniques for the intravitreal injection
Tehnike intravitrealnog ubrizgavanja
Techniques for the intravitreal injection
Tehnike primjene intravitrealne injekcije
Techniques for the intravitreal injection
tehnike za davanje intravitrealne injekcije
Tedizolid is a reversible inhibitor of MAO in vitro; however, no interaction is anticipated when comparing the IC50 and the anticipated plasma exposures in man.
Tedizolid je reverzibilan inhibitor monoaminoksidaze (MAO) in vitro; međutim, ne očekuju se interakcije kada se uspoređuje IC50 s očekivanim izloženostima u plazmi ljudi.
Tedizolid is a reversible inhibitor of monoamine oxidase (MAO) in vitro; however, no interaction is anticipated when comparing the IC50 for MAO-A inhibition and the anticipated plasma exposures in man.
Tedizolid je reverzibilan inhibitor monoaminoksidaze (MAO) in vitro; međutim, ne očekuju se interakcije kada se uspoređuje IC50 za inhibiciju MAO-A s očekivanim izloženostima u plazmi ljudi.
Tedizolid is excreted into the milk of lactating rats and the concentrations observed similar to those in maternal plasma.
Tedizolid se izlučuje u mlijeko ženki štakora u laktaciji, a opažene koncentracije bile su slične onima u majčinoj plazmi.
Tedizolid phosphate is generally not active against Gram-negative bacteria.
Tedizolidfosfat u pravilu nije aktivan protiv gram-negativnih bakterija.
Teduglutide has the advantage of lasting longer than GLP-2 in the body.
Teduglutid ima prednost što djeluje dulje od GLP-2 u tijelu.
Teduglutide was negative when tested in the standard battery of tests for genotoxicity.
Teduglutid je bio negativan kad je ispitan u standardnoj skupini testova genotoksičnosti.
Teduglutide was not associated with effects on reproductive performance, in utero or developmental parameters measured in studies to investigate fertility, embryo-fetal development and pre- and post-natal development.
Teduglutid nije bio povezan s djelovanjem na reprodukciju, in utero ili na razvojne parametre izmjerene u ispitivanjima plodnosti, embriofetalnog razvoja i pred- i postnatalnog razvoja.
Teduglutide works in a similar way to GLP-2 and increases intestinal absorption by: increasing blood flow to and from the gut, reducing the speed at which food passes through and reducing acid secretions in the stomach which can interfere with absorption in the intestine.
Teduglutid djeluje na sličan način kao GLP-2 i povećava apsorpciju crijeva povećanjem protoka krvi do i iz crijeva, smanjenjem brzine kojom hrana prolazi kroz crijeva i smanjenjem sekrecije želučane kiseline u želucu koja može djelovati na apsorpciju u crijevima.
TEE- guided (1 - 5 days of pre- treatment) or conventional cardioversion (at least three weeks of pre-treatment) strategies were employed.
Korištene su strategije kardioverzije vođene transezofagealnim ehokardiogramom (s prethodnim liječenjem 1 – 5 dana) ili konvencionalne kardioverzije (s prethodnim liječenjem najmanje 3 tjedna).
teeth grinding (bruxism), confusion, depressed mood, depression, disorientation (e.g. difficulty sensing time, direction, and recognition of people and places), early morning awakening, reduced emotional expressiveness (flat affect), hallucination, impulsive behaviour, indifference, insomnia, restlessness, disturbed sleep
škripanje zubima (bruksizam), smetenost, depresivno raspoloženje, depresija, dezorijentiranost (npr. teškoće s osjećajem za vrijeme, smjer i prepoznavanje osoba i mjesta), rano jutarnje buđenje, smanjena emocionalna ekspresivnost (zaravnjeni afekt), halucinacije, impulzivno ponašanje, ravnodušnost, nesanica, nemir, poremećeno spavanje
Tegafur is a prodrug of 5-FU with good oral bioavailability.
Tegafur je predlijek 5-FU-a s dobrom oralnom bioraspoloživošću.
Tel + 385 (0)1 5625 501
Tel: + 385 (0) 1 5625 501
Tel + 44 (0) 800 055 6614 e-mail medinfouk@shire.com
Tel. + 44 (0) 800 055 6614 e-mail: medinfouk@shire.com
Tel +353 61 585100
Tel +353-61-585100
tel +44 1753 888 567
Tel. +44 1753 888 567
Tel : +353 (0)14004141
Tel : +353 (0)14004141 info@nordicpharma.ie
Tel : +39 02 903731/800 985 597
77772828 ή +357-22482330 info@cy.linde-gas.com
Tel : +46 8 545 80 230
Tel : +46 (0)8 545 80 230
Tel. +34 93 544 85 07
Tel.: +34 93, Faks:85 07
Tel. +385 1 6274 220
Tel: +351 21 499 7400
Tel. +420 541 426 370
+43 +420 541 426 370
Tel. +43- (0) 1 80 105 0
Tel. +43- (0) 1 80 105 09
Tel. : +32 3 7806390
Telefon: +32 3 7806390
Tel.: (+48 22) 512 29 00
Tel.: (+ 48 22) 512 29 00
Tel.: + 0048 22 345 67 89
Τηλ: + 0030 210 6542909
Tel.: + 33 (0)4 91 08 69 30
Tel: + 34 913756230 Tel.: + 33 (0)4 91 08 69 30
Tel.: + 36 1 488 37 00
Tél/Tel: +32 (0)2 554 62 11
Tel.: + 361 (0) 355 8490
Tlf: + 46 (0)8 643 67 66 (SE)
Tel.: + 386 (0)1 52 11 400
Tel.: 386 (0)1 52 11 400
Tel.: + 44 (0) 845 676 1400 (Nagy-Britannia)
Tél/Tel: + 32 (0) 2 502 58 04 (Belgique/Belgien)
Tel.: + 44 (0)845 676 1400 (Nagy-Britannia)
Tél/Tel: + 32 (0) 2 502 58 04 (Belgique/Belgien)
Tel.: + 48 22 209 70 00
Tel.: + 48 22 209 70 00 biuro.pl@sandoz.com
Tel.: + 48 22 70 28 200 angelini@angelini.pl
Tel: + 34 93 253 4500 Tel.: + 48 22 70 28 200 angelini@angelini.pl
Tel.: + 48 22 8 333 177
Tel: + 48 22 8 333 177
Tel.: +36 1 239 9095
Tel: +36 1 239 9095
Tel.: +36 1 288 64 00
Tel.: +48 22 345 93 00
Tel.: +36 1 288 64 00
Tel: +36 1 288 64 00
Tel.: +36 1 288 64 00
ЕООД Tel.: +36 1 288 64 00
Tel.: +36 1 299 89 00
Tel: +36 1 299 8900
Tel.: +36 1 35 44 700
Amgen Switzerland AG Vilniaus filialas Tel: +372 5125 501
Tel.: +36 1 888 5300 hungary_msd@merck.com
Tel.: +36 1 430 2890888 5300 info.hungary_msd@sandozmerck.com
Tel.: +36 23501301
UAB “BERLIN-CHEMIE MENARINI BALTIC”
Tel.: +36-(0) 23530540 medicus@vetcentre.com
Tel: +36 (0) 23530540 medicus@vetcentre.com
Tel.: +36-1-488-37-00
Tlf: +45 44 20 11 00
Tel.: +361 2707030
Tel.: +36 1 270 7030
Tel.: +385 (0)1 3016 222
Tel: +385 (0)1 3016 222
Tel.: +420 283 004 111
Tel.: +420 -283- 004- 111
Tel.: +420 283 004 111
Tel.: +420-283-004-111
Tel.: +421 2 58282010 dpoc_czechslovak @merck.com
Tel.: +421 2 58282010 msd_sk@merck.com
Tel.: +48 (0) 22 440 33 00
Tel: + 36 1 328 5100
Tel.: +48 22 213 22 65
Tel: +48 22 213 22 65
Tel.: +48 22 335 61 00
Tel: +43 (0)1 521 15-0
Tel.: +48 22 345 93 00
Tel.: + 48 22 345 93 00
Tel.: +48 22 345 93 00
Tel: +39 028917981
Tel.: +48 22 345 93 00
Tel: +48 22 345 93 00
Tel.: +48 22 372 78 00
Tel.: + 48 22 372 78 00
Tel.: +48 22 372 78 00
Tel: +354 535 7000
Tel.: +49 (0) 800 825 3325 medinfo@takeda.de
Tel.: + 420 234 722 722
Tel.:+36 1 455 8600
Tel.: + 36 1 455 8600
Tel.:+36 1 884 2858
Tel. :+36 1 884 2858
Tel/Tél: +32 53 72 92 00 ferringnvsa@ferring.be
Tel/Tél : +32-53729200 ferringnvsa@ferring.be
Tel: (+49) 731 402 08
Tel: (49) 731 402 08
Tel: (351) 243 570 500
+ 351 219 245 020
Tel: + +39/02-61246921
Tel: + 39/02-61246921
Tel: + 31 (33 299 7080
Tel: + 31 33 299 7080
Tel: + 32 479 96 06 20 (België)
Tel: + 420 274 770 201
Tel: + 33 (0) 4 92 08 73 00
Tel: + 45 7552 1244
Tel: + 34-91 663 50 00
Te: + 34-91 663 5000
Tel: + 34-91 663 50 00
Tel: + 34 -91 663 50 00
Tel: + 34-91 663 50 00
Tel: + 34-91 663 5000
Tel: + 351 21 412 72 26
Tel: +351 21 412 72 26
Tel: + 356 21 22 01 74
Tel.: + 36 1 488 37 00
Tel: + 356 21 445 885
Tel: + 356 21 445 855
Tel: + 356 25600 500
Tel: + 356 50600 500
Tel: + 385 (0) 1 2303 446
Tel: +385 (0) 1 2303 446
Tel: + 385 1 3908 777 Tel: + 386 (0)1 52 11 400
Tel: + 385 1 3908 777 Tel: +40 (0)21 207 28 00
Tel: + 385 1 4821 361
Tel : + 385 1 4821 361
Tel: + 385 1 6051 999
Tel.: + 385 (0)1 605 19 99
Tel: + 385 1 6051 999
Tel.: + 385 (0)1 6051 999
Tel: + 385 1 6051 999
Tel: ++385 1 6051 999
Tel: + 385 1 6051 999
Tél.: + 385 (0)1 605 19 99
Tel: + 385 1 6611 333 croatia_info@merck.com
Tel: +385 1 6611 333 croatia_info@merck.com
Tel: + 385 1 670 01 02
Tel: +351 21 4401320
Tel: + 386 (0) 1 280 25 00 medical.x.si@gsk.com
Tel: + 386 (0)1 280 25 00 medical.x.si@gsk.com
Tel: + 386 (0)1 580 00 10
Tel: + 386 (0) 1 580 00 10
Tel: + 386 1 236 31 85
Tel: +386 1 236 31 85
Tel: + 420 274 770 201
Tel: + 32 479 96 06 20 (België)
Tel: + 421 2 326 04 910/ +421 917 206 274
Tel: +421 2 326 04 910/ +421 917 206 274
Tel: + 43 (0) 1 535 1980-0
Tlf: + 46 (0) 8 501 01 600 (Sverige)
Tel: + 43 (0) 1 711 780
Tél: + 33-(0) 1 55 49 34 34
Tel: + 43 (0)1 86 390 0
Tel: +31 (0)20 751 65 00
Tel: + 43 (0)53382000
Tel: +372 6652400 Tel: + 43 (0)53382000
Tel: + 44 (0) 1628 515500
+44 (0) 1304 616161
Tel: + 44 (0) 1628 515500
Tel:+ 44 (0) 1628 515500
Tel: + 44 (0) 208 600 1400 (Velika Britanija)
Tel: + 44 (0) 208 600 1400 (Ujedinjeno Kraljevstvo)
Tel: + 44 (0)1896 664000
Tel: + 44 (0) 1896 664000
Tel: + 44 1223 891854
Tel: +44 1223 891854
Tel: + 44 1707 853000 (United Kingdom)
Tel: + 44 1707 853000 (Ujedinjeno Kraljevstvo)
Tel: + 45 43 430355
Tel. + 45 43 430355
Tel: + 45 7552 1244
ET - 76505 Saue/Harjumaa, ESTONIA Tel: + 372 6 709 006
Tel: + 46 (0)40-650 15 00
Tel: + 46(0)40-650 15 00
Tel: + 46 8 545 80 230
Tel : +46 8 545 80 230
Tel: + 46 855 522 750 (Sverige)
Tel: + 46 855 522 750 (Sverige
Tel: + 48 (0) 22 440 33 00
Tel: +385 1 2350 999
Tel: + 48 22 546 64 00
Tel.: + 48 22 546 64 00
Tel: + 49 241 569-1111 service@grunenthal.com
Grünenthal GmbH Tel.: + 49 241 569-0
Tel: + 49 8024 908-0
Tel: +49 8024 908-0
Tel: + 49-(0) 6151 9512 0
Tel: +49-(0) 6151 9512 0
Tel: + 49-89-289 139-08 info@itg-garching.de
Tel:. + 49-89-289 139-08 info@itg-garching.de
Tel: +(39) 028917981
Tel: +(39) 0289179805
Tel: +(421) 2 5726 7911
Tel: +(421) 2 5726 7911Tel: +386 1 58 90 390
Tel: +(44) 1323 501 111
Tel: + 44(0) 1977 628500
Tel: +(44) 1977628500
Tel: +(44) 1323 501 111
Tel: ++43-(01)-728 03670 office@vana.at
Tel: +43 (01) 728 03670 office@vana.at
Tel: +30 210 6219520
Tel: + 30 210 6219520
Tel: +30 210 66 04 300
Tel.: +30 210 66 04 300
Tel: +31 (0) 342 427 127
Esperantolaan 4 B-3001 Leuven
Tel: +31 (0)10 406 43 01
Tel: + 356 21 22 01 74
Tel: +31 (0)76 5732500
Tel.: +36 1 35 44 700
Tel: +31 (0)88 322 2843
Tel: + 31 (0) 88 322 2843
Tel: +31 (0)88 322 2843
Tel: + 31 (0)88 322 2843
Tel: +31 (0)88 322 2843
Tel: +353 (0)1 428790
Tel: +31(0)13 5079 558
Tel.: +31(0)13 5079 558
Tel: +32 (0)2 722 97 98
Tél/Tel: + 32 (0)2 722 97 98
Tel: +33 1 47 73 64 58
Tél : +33 1 47 73 64 58
Tel: +34 91 387 70 00 es0-Registros@ferring.com
Tel: +34 91 387 7000 es0-Registros@ferring.com
Tel: +34 91 490 99 00
Tel: + 385 1 3908 777
Tel: +351 (0)21 1908400
Tel: + 351 (0) 21 1908400
Tel: +351 (0)21 1908400
Tel: + 351 (0)21 1908400
Tel: +351 (0)21 1908400
Tel: + 353 (0) 1 4287900
Tel: +351 (0)21 1908400
Tel: +39 06 928921
Tel: +351 / 214 72 63 00
Tel: +39 02 4305 1
Tel: +351 21 4172121
PT-2794-003 Carnaxide Tel: +351 21 4172121
Tel: +351 21 4220550
Tel: + 385 (0)1 562 57 20
Tel: +351 21 4401320
Tel: + 385 1 670 01 02
Tel: +351 21 476 75 50
Teva Pharma - Produtos Tel: +351 21 476 75 50
Tel: +351 21 499 7400
Tel. +385 1 6274 220
Tel: +351 21 940 5190 geral@ferring.com
Tel: +351 21 940 51 90 geral@ferring.com
Tel: +351-21-416 42 00
Sími: +354-540 80 00
Tel: +353 (0)1 4287900
Tel: + 353 (0) 1 4287900
Tel: +353 (0)1 4287900
Tel: + 353 (0)1 4287900
Tel: +353 (0)1 4287900
Tlf: + 47 67 81 80 00
Tel: +353 (0)1 663 8110
Tel: +353 (0)16638110
Tel: +353 1253 0660 info@retrophin.com
Tel: +353 1253 0660 info@ retrophin.com
Tel: +353 1800 633 363 (toll free)
Tel: +353 1800 633 363 (toll free) Pfizer, podružnica za svetovanje s področja
Tel: +353-(0)1 46 37 395
Tel: +353-(0)1-46 37 395
Tel: +354 535 7000
Tel: + 354 535 7000
Tel: +356-21 37 64 36
Tel: +49-(0)214-30 513 48
Tel: +356-21 37 64 36
Tel: +49-(0)214-30 513 488
Tel: +35621693533
Tel: + 35621693533
Tel: +357 24813333
Via Caldera, 21 I-20153 Milano
Tel: +36 - 23 446 800
Tel: +420 - 2 20382111 Tel: +36 - 23 446 800
Tel: +36-(0) 23530540 medicus@vetcentre.com
Tel: +36 (0) 23530540 medicus@vetcentre.com
Tel: +361 224 5222
Tel: +361 488 3695 224 5222
Tel: +370 37 473922
Tel: +370 37 473 922
Tel: +370 37 473922
Tel: +370 37 473922 1